Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JAB-30355 by Jacobio Pharmaceuticals Group for Solid Tumor: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Solid Tumor. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Small-Cell Lung Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Small-Cell Lung Cancer. According to...
JAB-30355 by Jacobio Pharmaceuticals Group for Gastric Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Gastric Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Pancreatic Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Ovarian Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Ovarian Cancer. According to GlobalData,...
JAB-30355 by Jacobio Pharmaceuticals Group for Breast Cancer: Likelihood of Approval
JAB-30355 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Breast Cancer. According to GlobalData,...